Dr. Vivien Bonazzi Named Chief Data Officer at Inari
Prior to joining Inari, Dr. Vivien Bonazzi served as chief biomedical data scientist and managing director at Deloitte Consulting LLP.
April 3, 2025
EXECUTIVES
As the medical device industry rapidly expands, so does the need for executive leadership. Recently, several top executives have made moves within the industry. Some have taken new positions at other companies, while others have started their own businesses. Here’s a look at who’s been making headlines lately.
InfuSystem Announces CEO Transition | Carrie Lachance to Become CEO Effective May 19, 2025
“Carrie Lachance has been at the center of InfuSystem’s succession plan for the past several years, and she is the ideal person to succeed Rich DiIorio having spent the last decade plus working her way up through ever greater positions of responsibility within the Company,” said Scott Shuda, Chairman of the board of InfuSystem.
April 1, 2025
ITM Appoints Dr. Celine Wilke Chief Medical Officer
“Celine brings a wealth of experience in advancing radiopharmaceutical precision oncology treatments from early development through to regulatory approval. As she steps into the leadership of our medical team, her expertise will be instrumental in progressing our pipeline and delivering new treatment options for patients,” said Dr. Andrew Cavey, Chief Executive Officer of ITM.
April 1, 2025
Nuage Therapeutics Appoints Dr. Stuart Hughes CEO and Vanessa Malier as Chair
Nuage Therapeutics applying its proprietary technology to advance a pipeline of novel agents targeting oncogenic transcription factors.
April 1, 2025
Olga Uspenskaya-Cadoz Appointed Chief Medical Officer of VectorY Therapeutics
Dr. Uspenskaya-Cadoz brings two decades of experience in neurology, gene therapy, and clinical development, enhancing VectorY’s leadership in developing transformative treatments for neurodegenerative conditions.
April 1, 2025
Operation Warp Speed Leader Tapped as Panther Life Sciences’ New R&D Chief | The Appointment of Dr Matthew Hepburn to Expand Panther’s Leadership For Next Generation Immune-Mediated Therapies
In this role, Dr Martin Hepburn will drive Panther’s strategic commitment to commercialize its patented MAP technology, with a primary focus on reducing time-to-market and delivering the first commercial product to customers within the next two years.
March 27, 2025